Bupropion extended release compared with escitalopram: effects on sexual functioning and antidepressant efficacy in 2 randomized, double-blind, placebo-controlled studies
| Autor: | Jack G. Modell, Nathalie Richard, Joseph P. Horrigan, Alok Krishen, Donna S. Wightman, Anita H. Clayton, Harry A. Croft |
|---|---|
| Rok vydání: | 2006 |
| Předmět: |
Adult
Male medicine.medical_specialty Sexual Behavior Citalopram Placebo Drug Administration Schedule Placebos Double-Blind Method Internal medicine mental disorders medicine Clinical endpoint Ambulatory Care Escitalopram Humans Prospective Studies Sexual Dysfunctions Psychological Bupropion Retrospective Studies Psychiatric Status Rating Scales Depressive Disorder Major Hamilton Rating Scale for Depression medicine.disease Psychiatry and Mental health Treatment Outcome Tolerability Anesthesia Delayed-Action Preparations Major depressive disorder Antidepressive Agents Second-Generation Female Reuptake inhibitor Psychology Selective Serotonin Reuptake Inhibitors medicine.drug |
| Zdroj: | The Journal of clinical psychiatry. 67(5) |
| ISSN: | 0160-6689 |
| Popis: | Objective: To compare the effects on sexual functioning and the antidepressant efficacy of once-daily bupropion extended release (XL) and escitalopram in adults with major depressive disorder (MDD). Method: Adult outpatients with moderate to severe DSM-IV-defined MDD and normal sexual functioning were randomly assigned to receive bupropion XL (300-450 mg/day; N = 276), escitalopram (10-20 mg/day; N = 281), or placebo (N = 273) for up to 8 weeks in 2 identically designed, randomized, double-blind, parallel-group studies (study 1 conducted from February 6, 2003, to June 10, 2004; study 2 conducted from January 21, 2003, to June 15, 2004). Data were analyzed prospectively for each study individually, and pooled data were analyzed retrospectively. Results: In both the individual studies and the pooled dataset, the incidence of orgasm dysfunction at week 8 (primary endpoint) and the incidence of worsened sexual functioning at the end of the treatment period were statistically significantly lower with bupropion XL than with escitalopram (p |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|